PHA-767491抑制CDC-7的表达在子宫内膜癌ishikawa细胞系中的作用研究

doi:10.12092/j.issn.1009-2501.2019.08.004

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (8): 866-871.doi: 10.12092/j.issn.1009-2501.2019.08.004

PHA-767491抑制CDC-7的表达在子宫内膜癌ishikawa细胞系中的作用研究

王庆玮，丁锦，吕爰爰，罗贤臣，倪观太

皖南医学院第一附属医院妇产科，芜湖 241000，安徽

收稿日期:2019-01-14 修回日期:2019-02-27 出版日期:2019-08-26 发布日期:2019-08-30
通讯作者: 倪观太，男，副教授，硕士生导师，研究方向：妇科肿瘤及盆底疾病。 E-mail：ngtiger@aliyun.com
作者简介:王庆玮，女，硕士研究生，研究方向：妇科肿瘤及盆底疾病。 Tel:13505595719 E-mail:wqw0116@126.com
基金资助:
安徽省高校自然科学类重点科研项目（KJ2018A0267）

Effects of PHA-767491 on the inhibition of CDC-7 expression in endometrial cancer ishikawa cell line

WANG Qingwei, DING Jin, LV Yuanyuan, LUO Xianchen, NI Guantai

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Wannan Medical College, Wuhu 241000, Anhui, China

Received:2019-01-14 Revised:2019-02-27 Online:2019-08-26 Published:2019-08-30

摘要/Abstract

摘要：

目的:PHA-767491抑制CDC-7的表达对子宫内膜癌ishikawa细胞系的增殖、侵袭、迁移以及凋亡产生的作用。方法:配置PHA-767491至各实验所需浓度，使其作用于子宫内膜癌ishikawa细胞系。CCK-8法用于检测ishikawa细胞系的增殖能力及明确IC50。运用qRT-PCR法，检测药物PHA-767491对ishikawa细胞中的CDC-7 mRNA的表达的影响。利用划痕实验，检测PHA-767491对于ishikawa细胞迁移能力的影响。用Transwell法检测药物影响ishikawa细胞的侵袭能力。流式细胞术Annexin V/PI双染色法检测药物PHA-767491影响ishikawa细胞的凋亡能力。结果:CCK-8的结果得出，药物PHA-767491能够有效地抑制ishikawa细胞系增殖的能力，得出24 h药物IC50等于9.51 μmol/L。qRT-PCR的结果证明：PHA-767491抑制ishikawa细胞中CDC-7 mRNA的显著表达。划痕实验的结果表明：PHA-767491可抑制ishikawa细胞的迁移能力。Transwell结果表明：药物PHA-767491有效地抑制ishikawa细胞的侵袭能力。流式细胞术结果证明：PHA-767491可以促进ishikawa细胞的凋亡。结论:PHA-767491能够显著抑制子宫内膜癌细胞ishikawa中CDC-7的表达，降低了ishikawa细胞增殖和迁移、侵袭能力，并且可明确诱导ishikawa细胞的凋亡。

关键词: PHA-767491, CDC-7, 子宫内膜癌, 增殖, 迁移, 侵袭, 凋亡

Abstract:

AIM: To investigate the effects of PHA-767491 on the inhibition of CDC7 expression on proliferation, invasion, migration and apoptosis of endometrial cancer ishikawa cell line. METHODS: Different concentrations of PHA-767491 were used to treat the endometrial cancer ishikawa cell line. The proliferation ability of ishikawa cells and the IC50 were determined by CCK-8 method. RT-PCR was used to detect the effect of PHA-767491 on the expression of CDC-7 mRNA in ishikawa cells. The migration ability of the cells was then examined using a scratch test. The transwell chamber method was applied to detect the invasive ability of ishikawa cells.Flow cytometry Annexin V/PI double staining was used to detect cell apoptosis. RESULTS:The results of CCK-8 assay showed that PHA-767491 significantly inhibited the proliferation of endometrial cancer ishikwa cells with an IC50 of 9.51 μmol/L at 24 hours. RT-PCR showed that PHA-767491 significantly inhibited the expression of Cdc-7 mRNA in ishikawa cells. Scratch test showed that PHA-767491 effectively inhibited the migration ability of ishikawa cells. Transwell chamber results showed that PHA-767491 inhibited the invasion of ishikawa cells.PHA-767491 significantly induced ishikawa cells apoptosis.CONCLUSION: PHA-767491 can significantly inhibit the expression of CDC-7 in ishikawa of endometrial cancer cells, which can significantly reduce the proliferation, migration and invasion and induce apoptosis of ishikawa cells.

Key words: PHA-767491, CDC-7, endometrial cancer, proliferation, migration, invasion, apoptosis

中图分类号:

R737.3

王庆玮，丁锦，吕爰爰，罗贤臣，倪观太. PHA-767491抑制CDC-7的表达在子宫内膜癌ishikawa细胞系中的作用研究[J]. 中国临床药理学与治疗学, 2019, 24(8): 866-871.

WANG Qingwei, DING Jin, LV Yuanyuan, LUO Xianchen, NI Guantai. Effects of PHA-767491 on the inhibition of CDC-7 expression in endometrial cancer ishikawa cell line[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 866-871.

参考文献

［1］Wójcik-Krowiranda KM, Szczepaniec S, Bieńkiewicz A. The role of the βKlotho gene in uterine endometrial cancer［J］. Ginekol Pol, 2018, 89(10): 563-567.
［2］Packer LM, Stehbens SJ, Bonazzi VF, et al. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2 mutant endometrial cancer［J］. Mol Oncol, 2019 ,13(4):738-756.
［3］Tenca P, Brotherton D, Montagnoli A, et al. CDC7 is an active kinase in human cancer cells undergoing replication stress［J］. J Biol Chem, 2007,282(1):208-215.
［4］Tudzarova S, Mulholland P, Dey A, et al. p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress［J］. Cell Cycle, 2016,15(21):2958-2972.
［5］Li W, Zhao XL, Shang SQ, et al. Dual inhibition of Cdc7 and Cdk9 by PHA-767491 suppresses hepatocarcinoma synergistically with 5-Fluorouracil［J］. Curr Cancer Drug Targets, 2015, 15(3):196-204.
［6］徐瑞云，严晓丽，石建芹,等. CDC7和MCM4在子宫内膜腺癌中的表达及意义［J］.中国妇幼保健,2016, 31(5):1048-1051.
［7］Moore K, Brewer MA. Endometrial cancer: Is this a new disease［J］. Am Soc Clin Oncol Educ Book, 2017,37:435-442.
［8］Sclafani RA, Holzen TM. Cell cycle regulation of DNA replication［J］. Annu Rev Genet, 2007,41:237-280.
［9］Labib K. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells［J］? Genes Dev, 2010, 24(12):1208-1219.
［10］Kulkarni AA, Kingsbury SR, Tudzarova S, et al. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma［J］. Clin Cancer Res, 2009,15(7):2417-2425.
［11］Melling N, Muth J, Simon R, et al. Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer［J］. Diagn Pathol, 2015,10:125.
［12］Datta A, Ghatak D, Das S, et al. p53 gain-of-function mutations increase Cdc7-dependent replication initiation［J］. EMBO Rep, 2017, 18(11):2030-2050.
［13］Jaafari-Ashkavandi Z, Ashraf MJ, Abbaspoorfard AA. Overexpression of CDC7 in malignant salivary gland tumors correlates with tumor differentiation［J］. Braz J Otorhinolaryngol, 2019,85(2):144-149.
［14］Choschzick M, Lebeau A, Marx AH, et al. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer［J］. Hum Pathol, 2010,41(3):358-365.
［15］Bonte D, Lindvall C, Liu H,et al. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation［J］. Neoplasia, 2008, 10(9):920-924.
［16］Montagnoli A, Tenca P, Sola F, et al. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells［J］.Cancer Res, 2004,64(19):7110-7116.
［17］Im JS, Lee JK. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7［J］. J Biol Chem, 2008, 283(37):25171-25177.
［18］Sasi NK, Bhutkar A, Lanning NJ, et al. DDK Promotes tumor chemoresistance and survival via multiple pathways［J］.Neoplasia,2017,19(5):439-450.
［19］Swords R, Mahalingam D, O'Dwyer M, et al. Cdc7 kinase-a new target for drug development［J］. Eur J Cancer, 2010, 46(1):33-40.
［20］Montagnoli A, Moll J, Colotta F. Targeting cell division cycle 7 kinase:a new approach for cancer therapy［J］. Clin Cancer Res, 2010, 16(18):4503-4508.
［21］Montagnoli A, Valsasina B, Croci V, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity［J］.Nat Chem Biol, 2008,4(6):357-365.

[1]	范杰, 金永明, 江孝龙, 蒋国华. lncRNA HOTAIR调控miR-206影响类风湿关节炎滑膜细胞增殖和凋亡的分子机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 736-742.
[2]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[3]	杨晓佳, 江萌, 吴敏, 张伊黎, 吕兰, 吴嫄芬, 王鑫昱, 刘立权. 藏红花素介导DKK3调控GSK-3β/β-catenin通路对阿尔兹海默症大鼠的认知改善作用[J]. 中国临床药理学与治疗学, 2023, 28(5): 489-497.
[4]	王艳, 张金辉, 赵永辰, 刘宏祥, 刘亚维, 苗欢欢, 杨信才. 红杉黄酮通过下调PI3K/AKT信号通路抑制胃癌细胞增殖侵袭等干细胞特性[J]. 中国临床药理学与治疗学, 2023, 28(5): 508-513.
[5]	周晶, 周琛, 廖珂, 邱爱林, 董巍檑, 郭紫芬. 孕激素受体基因G1978T 多态性与子宫内膜癌的相关性研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 400-406.
[6]	侯小煜, 冷玉芳, 曹雪芬, 吕兴娇, 韩晓霞, Janvier NIBARUTA, 刘永强. 五味子乙素减轻小鼠肠缺血再灌注损伤的网络药理学分析及实验验证[J]. 中国临床药理学与治疗学, 2023, 28(2): 147-154.
[7]	王剑, 孙永东, 周兴玮, 刘雷, 陈龙, 童兴科, 朱佳丽. 黄芩素经由miR-125b-5p/IRF4轴进而促进喉癌细胞死亡并抑制其侵袭的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1209-1218.
[8]	朱瑞芳, 郭东凯, 智慧, 江翊国, 张悦翎, 钱晓萍, 季士亮. ROS-NF-κB-p38MAPK通路探索榄香烯联合硼替佐米抗多发性骨髓瘤的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1219-1226.
[9]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[10]	周欢, 徐铭, 李波, 刘春英, 王淳. PI3K/Akt/FOXO3a信号通路介导的保护性自噬参与肺腺癌获得性顺铂耐药表型重塑[J]. 中国临床药理学与治疗学, 2022, 27(9): 961-970.
[11]	华海燕, 严杰, 秦宇芬. 五味子乙素通过抑制心肌细胞凋亡减轻大鼠心肌缺血再灌注损伤的实验研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 848-856.
[12]	丁嘉敏, 王友娣, 赵夏丽, 姜根风, 陈思文, 洪程程, 李书勤, 胡卫华. 生长激素和维生素E联合应用治疗薄型子宫内膜的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 857-862.
[13]	眭玉霞, 庄捷, 庄敏, 黄桂. Delicaflavone通过PI3K/AKT/mTOR通路调控上皮-间质转化抑制吉非替尼耐药肺癌PC-9/GR细胞迁移和侵袭[J]. 中国临床药理学与治疗学, 2022, 27(6): 614-621.
[14]	李雪恒, 李龙. 褪黑素与特发性肺纤维化关系的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(6): 715-720.
[15]	王新丽, 许霞青, 方寒冰, 郭玉忠. 佛波酯增强顺铂的抗肿瘤活性及降低其肾毒性的作用研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 535-543.

PHA-767491抑制CDC-7的表达在子宫内膜癌ishikawa细胞系中的作用研究

Effects of PHA-767491 on the inhibition of CDC-7 expression in endometrial cancer ishikawa cell line

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价